In patients with hypercortisolism and inadequately controlled type 2 diabetes, mifepristone lowered HbA1c levels by about 1.5 ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

Hims & Hers stock crashes 30% on Monday after news of Novo Nordisk ending their partnership. Is HIMS now a compelling stock ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Hims & Hers Health Inc.'s stock was headed for a record session of losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

The endocrinologist and researcher was one of several investigators who presented Phase 3 clinical trial results at the 85th Scientific Sessions of the American Diabetes Association for a long-lasting ...

Several major U.S. health insurers announce they will voluntarily speed up and simplify the prior authorization process.

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

A common blood test can flag early Alzheimer's disease patients who are four times more likely to experience rapid brain ...

Hims & Hers ( HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk ( NVO) announced it was ending a ...